Choose Your Country or Region

Anti-SHP1 Rabbit Antibody [M15F6]

Catalog No.: F3759

Application: Reactivity: Mouse, Rat, Human

Usage Information

Dilution
WB1:1000 IHC1:100

Application
WB, IHC

Reactivity
Mouse, Rat, Human

Source
Rabbit

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
68 kDa 65 kDa, 70 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight.

Positive Control	Rat spleen; Mouse liver; Human tonsil; Human lymph node; Mouse marrow; Rat brain; Rat cerebral cortex; THP-1; Jurkat; K562; SP2/0; C6; A431
Negative Control

Datasheet & SDS

Biological Description

Specificity
SHP1 Rabbit mAb detects endogenous levels of total SHP1 protein. SHP1 Rabbit mAb is predicted to detect isoforms 1, 2 and 3 of human SHP1 based on sequence analysis.

Clone
M15F6

Synonym(s)
HCP, PTP1C, PTPN6, Tyrosine-protein phosphatase non-receptor type 6, Hematopoietic cell protein-tyrosine phosphatase, Protein-tyrosine phosphatase 1C, Protein-tyrosine phosphatase SHP-1, SH-PTP1, PTP-1C

Background
SHP-1 is a non-receptor protein tyrosine phosphatase that primarily functions as a negative regulator of inflammatory signaling. It is predominantly expressed in hematopoietic and epithelial cells and plays a well-established role in dampening pathways that govern cell proliferation, differentiation, survival, apoptosis, and adhesion. Because it counteracts the growth-promoting and oncogenic activity of tyrosine kinases, SHP-1 is considered a candidate tumor suppressor in lymphomas, leukemias, and various solid tumors. Structurally, SHP-1 contains two SH2 domains at the N-terminus, a catalytic phosphatase domain, and a C-terminal tail. Its activity is tightly controlled by an auto-inhibitory mechanism, in which the N-terminal SH2 domain inserts into the catalytic site, preventing enzymatic function. Upon binding of the SH2 domains to phosphorylated tyrosine residues on signaling proteins, SHP-1 undergoes conformational changes that relieve this inhibition, exposing the catalytic site and allowing full activation. As a key regulator of multiple signaling pathways, SHP-1 exerts broad effects across physiological and pathological processes. Its fundamental role lies in dephosphorylating signaling molecules to attenuate, rather than redirect, cellular activation, thereby fine-tuning the magnitude of responses. In the immune system, SHP-1 regulates both innate and adaptive immunity, and its influence extends beyond specific inflammatory contexts, highlighting its importance in maintaining balanced immune responses.

Background

SHP-1 is a non-receptor protein tyrosine phosphatase that primarily functions as a negative regulator of inflammatory signaling. It is predominantly expressed in hematopoietic and epithelial cells and plays a well-established role in dampening pathways that govern cell proliferation, differentiation, survival, apoptosis, and adhesion. Because it counteracts the growth-promoting and oncogenic activity of tyrosine kinases, SHP-1 is considered a candidate tumor suppressor in lymphomas, leukemias, and various solid tumors. Structurally, SHP-1 contains two SH2 domains at the N-terminus, a catalytic phosphatase domain, and a C-terminal tail. Its activity is tightly controlled by an auto-inhibitory mechanism, in which the N-terminal SH2 domain inserts into the catalytic site, preventing enzymatic function. Upon binding of the SH2 domains to phosphorylated tyrosine residues on signaling proteins, SHP-1 undergoes conformational changes that relieve this inhibition, exposing the catalytic site and allowing full activation. As a key regulator of multiple signaling pathways, SHP-1 exerts broad effects across physiological and pathological processes. Its fundamental role lies in dephosphorylating signaling molecules to attenuate, rather than redirect, cellular activation, thereby fine-tuning the magnitude of responses. In the immune system, SHP-1 regulates both innate and adaptive immunity, and its influence extends beyond specific inflammatory contexts, highlighting its importance in maintaining balanced immune responses.

References
https://pubmed.ncbi.nlm.nih.gov/34088320/ https://pubmed.ncbi.nlm.nih.gov/20077161/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%